98 Between the 154 patents wth gA dsease at baselne, medaTTwas sgnfcantly longer the lenaldomde plus dexamethasone grouthathe dexamethasone only group.101 patents wthout gA dsease, medaTTwas agasgnfcantly longer the lenaldomde plus dexamethasone groucompared wth dexamethasone alone.Patents wth a baselne ECOG score of 0 or 1 alsohad a sgnfcantly longer medaTTolenaldomde plus dexamethasone thadexamethasone alone.102 Dexamethasone dose reductowas smarly assocated wth a longer TTP.the pooled subgrouanalyss of patents wth renal mparment, medaTTwas sgnfcantly longer for lenaldomde plus dexamethasone compared wth dexamethasone alone patents wth regular renal functon, and md, moderate, and extreme renal mpar ment104.
another subgrouanalyss of patents who receved lenaldomde plus dexamethasone, dose reductoof dexamethasone was assocated wth sgnfcantly longer TTthacontnung dexamethasone accordng to your planned dosng routine.105 Sngle agent lenaldomde Amongst 222 patents enrolled the multcenter, opelabel phase MM 014 study, 69% of patentshad dsease pro gressoby more hints the end of the study wth a medaTTof 5.4 months.112 RAD a phase review of 41 patents treated for sx 28 day cycles wth lenaldomde 25 mg day odays one 21, doxorubc9 mg m2 odays one 4, dexamethasone 40 mg day odays one 4 and 17 twenty, and G CSF 6 mg oday six, medaTTafter a medafollow uof fve months was 9.three weeks.117 General survval Lenaldomde plus dexamethasone Relatve to dexamethasone alone, medaOS was sgnf cantly prolonged patents assgned to lenaldomde plus dexamethasone the two the MM 009 and MM 010 studes.2,3 At a medafollow upost randomzatoof 17.
1 months the MM 009 research, the medaOS patents assgned to lenaldomde plus dexamethasone was 29.6 months versus twenty.2 months for dexamethasone alone.3 Sm larly, selleck chemicals Bortezomib at a medafollow uof sixteen.5 months the MM 010 examine, the medaOS patents assgned to lenaldomde plus dexamethasonehad not beereached, whereas patents assgned to dexamethasone only medaOS was estmated at 20.6 months.2 Wth aextended stick to uof 31.three months, the medaOS for all 704 patents pooled from both studes was 35.0 months for those recevng lenaldomde plus dexamethasone and 31.0 months for all those odexamethasone alone.97 t really should be noted that ths sgnfcant dfference OS was mantaned despte 47% of patents recevng dexamethasone alone crossng more than to lenaldomde plus dexamethasone treatment.
97 Response was correlated wth survval given that amid patents assgned to lenaldomde plus dexamethasone the medaOS was sgnfcantlyhgher for those who acheved CR or nCR, thafor patents who acheved
a PR.98 both MM 009 and MM 010, OS was sgnfcantly mproved the lenaldomde plus dexamethasone groucompared wth the dexamethasone only group, among patents whohad prevously beetreated wth thaldomde.2,three addton, lenaldomde plus dexamethasone was assocated wth sgnfcantly longer OS compared wth dexamethasone alone, rrespectve from the variety of pror therapes.